Crossject's ZENEO® Auto-Injector: Proven in Extreme HAZMAT Conditions

In the realm of emergency medicine, efficiency and ease of use are paramount. Crossject, a specialty pharmaceutical company, has demonstrated the exceptional usability of its ZENEO® auto-injector in extreme HAZMAT conditions, further solidifying its position as a leader in emergency medicine solutions.

Crossject's ZENEO® auto-injector has been put to the test in a recent HAZMAT study, simulating a chemical attack zone or field hospital setting. The study, supported by federal funds from the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, and Biomedical Advanced Research and Development Authority (BARDA), confirmed the auto-injector's usability among untrained users in various high-risk scenarios. This usability is crucial for emergency responders, military personnel, and first responders, who may need to administer life-saving medicines in challenging conditions.

The ZENEO® auto-injector's performance in extreme conditions is a testament to its versatility and reliability. It can be rapidly and mass-administered by untrained caregivers, making it an invaluable tool in emergency situations. The device's needle-free design reduces the risk of needlestick injuries, further lowering healthcare costs. Additionally, its ability to deliver medications through clothing or bare skin increases its versatility, allowing for rapid, mass administration in high-risk scenarios.

Crossject's ZENEO® auto-injector is designed to enable patients or untrained caregivers to easily and instantly deliver a broad range of emergency medicines via intramuscular injection on bare skin or even through clothing. This usability, coupled with the device's advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, further solidifies Crossject's position as a leading specialty pharma company in the emergency medicine sector.

The successful HAZMAT study further validates Crossject's commitment to developing life-saving medicines for emergency situations. With a $60 million contract with BARDA for ZEPIZURE®, Crossject's versatile ZENEO® platform enables patients or untrained caregivers to easily and instantly deliver a broad range of emergency medicines via intramuscular injection on bare skin or even through clothing. The company's other products in development include mainly solutions for allergic shocks and adrenal insufficiencies, as well as therapies and other emergency indications.

In conclusion, Crossject's ZENEO® auto-injector has proven its usability in extreme HAZMAT conditions, demonstrating its suitability for rapid, mass administration by untrained caregivers in high-risk scenarios. This study, combined with an earlier human factors study in 2022, confirms the auto-injector's potential for widespread adoption by first responders and healthcare professionals in emergency situations. With its advanced regulatory development and versatile platform, Crossject is well-positioned to lead the specialty pharma market in emergency medicine solutions.